
each $\mathbf{R^g}$ is independently selected from the group consisting of: $\mathbf{R^h}$, oxo, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, OH, -(C_{0-3} alkylene)-C_{1-6} alkoxy, -(C_{0-3} alkylene)-C_{1-6} haloalkoxy, -(C_{0-3} alkylene)-NH_2, -(C_{0-3} alkylene)-N(H)(C_{1-3} alkyl), and –(C_{0-3} alkylene)-N(C_{1-3} alkyl)$_2$.

In one aspect, the present disclosure refers to a compound of Formula (**I-b-4**):



Formula (**I-b-4**)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{E^1}$ is C$\mathbf{R^{2a}}$;

$\mathbf{R^{2a}}$ and $\mathbf{R^{2b}}$ are each independently selected from the group consisting of: H and F;

–$(\mathbf{X^3})_{\mathbf{m3}}$-$\mathbf{R^1}$ is C_{1-3} alkyl;

$\mathbf{X^a}$ is N;

$\mathbf{R^6}$ is F or Cl;


m4 and **m5** are independently 0, 1, or 2;

each $\mathbf{R^{a4}}$ and $\mathbf{R^{a5}}$ is independently selected from the group consisting of: F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F;

$\mathbf{L^{A1}}$ is CH_2; and

$\mathbf{R^{Ya}}$ is C_{1-3} alkyl optionally substituted with 1-3 F.

Also provided herein are compounds of Formula (**II-a**):



Formula (**II-a**)

or pharmaceutically acceptable salts thereof, wherein:

$\mathbf{E^1}$ is C$\mathbf{R^{2a}}$ or N;

$\mathbf{R^{2a}}$ and $\mathbf{R^{2b}}$ are independently selected from the group consisting of: H, halo, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

m3 is 0 or 1;

$\mathbf{X^3}$ is C_{1-3} alkylene optionally substituted with 1-3 $\mathbf{R^c}$;

$\mathbf{R^1}$ is selected from the group consisting of: H, halo, and $\mathbf{R^{b1}}$;

$\mathbf{X^a}$ is selected from the group consisting of: N and C$\mathbf{R^{Xa}}$;

$\mathbf{R^6}$ and $\mathbf{R^{Xa}}$ are independently selected from the group consisting of: H, halo, C_{1-2} alkyl, C_{1-2} haloalkyl, C_{1-2} alkoxy, CN, and C≡CH;

$\mathbf{L^{A4a}}$ and $\mathbf{L^{A4b}}$ are independently 4-12 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 $\mathbf{R^a}$;

$\mathbf{L^{A1}}$ is CH_2, CH$\mathbf{R^L}$, or C($\mathbf{R^L}$)$_2$, and

each $\mathbf{R^L}$ is independently selected from the group consisting of: F, OH, and C_{1-3} alkyl optionally substituted with 1-3 $\mathbf{R^c}$;

each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, cyano, OH, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $N\mathbf{R^d}\mathbf{R^e}$, $C(=O)C_{1-6}$ alkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), and $S(O)_{0-2}(C_{1-6}$ haloalkyl);

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: H, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl, $C(=O)OC_{1-6}$ haloalkyl, $C(=O)N(\mathbf{R^f})_2$, $S(O)_{1-2}(C_{1-6}$ alkyl), $S(O)_{1-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(\mathbf{R^f})_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^g}$ is independently selected from the group consisting of: $\mathbf{R^h}$, oxo, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, cyano, OH, -(C_{0-3} alkylene)-C_{1-6} alkoxy, -(C_{0-3} alkylene)-C_{1-6} haloalkoxy, -(C_{0-3} alkylene)-NH_2, -(C_{0-3} alkylene)-N(H)(C_{1-3} alkyl), and –(C_{0-3} alkylene)-N(C_{1-3} alkyl)$_2$.

Also provided herein are pharmaceutical compositions comprising a compound of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**) (e.g., Formula (**I-e-1**) or (**I-e-2**))), Formula (**II**), or Formula (**II-a**) (e.g., Formula (**II-a-1**)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In one aspect, the present disclosure refers to a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Provided herein are methods for treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a compound of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**) (e.g., Formula (**I-e-1**) or (**I-e-2**))), Formula (**II**), or Formula (**II-a**) (e.g., Formula (**II-a-1**)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein.

In one aspect, the present disclosure refers to use of a compound disclosed herein or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein in the manufacture of a medicament for treating a cancer.

In one aspect, the present disclosure refers to a compound disclosed herein for use in therapy.

Also provided herein are BCL6 proteins non-covalently bound with a compound of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**) (e.g., Formula (**I-e-1**) or (**I-e-2**))), Formula (**II**), or Formula (**II-a**) (e.g., Formula (**II-a-1**)), or

a pharmaceutically acceptable salt thereof.

Also provided herein are ternary complexes comprising a BCL6 protein, a compound of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**) (e.g., Formula (**I-e-1**) or (**I-e-2**))), Formula (**II**), or Formula (**II-a**) (e.g., Formula (**II-a-1**)), or a pharmaceutically acceptable salt thereof, and a cereblon (CRBN) E3 ligase protein (also referred to herein as a CRBN protein), or a portion thereof.

To facilitate understanding of the disclosure set forth herein, a number of additional terms are provided. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties. In the case of conflict between the present disclosure and any content incorporated by reference, the present disclosure controls.

The details of one or more examples of the disclosure are set forth in the accompanying drawings and the description below. Other features and advantages of the disclosure will be apparent from the description and drawings, and from the claims.

DETAILED DESCRIPTION

This disclosure provides compounds of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**) (e.g., Formula (**I-e-1**) or (**I-e-2**))), Formula (**II**), or Formula (**II-a**) (e.g., Formula (**II-a-1**)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL6 protein. These compounds are useful, e.g., for treating a cancer. This disclosure also provides compositions containing compounds of Formula (**I**) (e.g., Formula (**I-1**), Formula (**I-2**), Formula (**I-a**) (e.g., Formula (**I-a-1**), (**I-a-2**), (**I-a-3**), or (**I-a-4**)), Formula (**I-b**) (e.g., Formula (**I-b-1**), (**I-b-2**), (**I-b-3**), or (**I-b-4**)), Formula (**I-c**) (e.g., Formula (**I-c-1**) or (**I-c-2**)), Formula (**I-d**) (e.g., Formula (**I-d-1**)), or Formula (**I-e**)